Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bio-Matrix Scientific Group, a biotechnology R&D company, and Entest BioMedical, a wholly owned subsidiary of Bio-Matrix Scientific Group, have signed a contract with Brian Koos, a professor of obstetrics and gynecology at the David Geffen School of Medicine at University of California, Los Angeles, for the development, refinement, and validation of a screening test for gestational diabetes.
Subscribe to our email newsletter
Dr Koos is the developer of a screening test for gestational diabetes licensed to Entest BioMedical by University of California, Los Angeles (UCLA). The screening test is believed to mitigate the lengthy process of diagnosing gestational diabetes and would allow for faster treatment of the disease. Entest is the exclusive licensee for Dr Koos’s gestational diabetes screening test.
Both companies stated that their goal is to develop a large scale sampling for validation of the screening test with the FDA. The gestational diabetes screening test would be marketed to hospitals and medical clinics.
Dr Koos said: “There is a very large potential market for our screening test. Gestational diabetes is diabetes that is found for the first time when a woman is pregnant. Out of every 100 pregnant women in the US, three to eight get gestational diabetes. This non-invasive screening test for gestational diabetes, which is very reliable, is highly accurate in identifying women with gestational diabetes.”